Fever, bacterial zoonoses, and One Health in sub-Saharan Africa

Authors: Manuela Carugati, Kajiru G Kilonzo and John A Crump

Although often underappreciated, a number of bacterial zoonoses are endemic in Africa. Of these, brucellosis, leptospirosis, Q fever, and rickettsioses are responsible for a substantial proportion of febrile illness among patients seeking hospital care. In this paper, we discuss the aetiology, epidemiology, clinical presentation, diagnosis, treatment and prevention of these bacterial zoonoses. To prevent and control bacterial zoonoses, strategies targeting both animals and humans are crucial. These may lead to better outcomes than strategies based exclusively on treatment of human infections. Such strategies are referred to as the ‘One Health’ approach; the collaborative effort of multiple disciplines to attain optimal health for people, animals and the environment.

Keywords: sub-Saharan Africa, zoonoses, fever, One Health, brucellosis

The patient with fever in sub-Saharan Africa

Fevers are a common symptom among patients seeking healthcare in sub-Saharan Africa where it may occur with or without localising features. With declines in malaria incidence worldwide and the wider availability of malaria diagnostic tests, the problem of malaria over-diagnosis has become apparent. Studies to the wider availability of malaria diagnostic tests, the problem of malaria over-diagnosis has become apparent. With declines in malaria incidence worldwide and in sub-Saharan Africa where it may occur with or without localising features. 2,3 Studies to describe major non-malaria causes of severe febrile illness in sub-Saharan Africa have identified the importance of bacterial bloodstream infections, HIV coinfections such as cryptococcal disease and disseminated tuberculosis, arbovirus infections and bacterial zoonoses such as brucellosis, leptospirosis, Q fever and rickettsioses. 4,5 For example, research among 870 inpatients admitted with fever in northern Tanzania showed that malaria was the cause of fever in 14 (1.6%) participants, while bacterial, mycobacterial and fungal bloodstream infections accounted for 85 (9.8%), 14 (1.6%) and 25 (2.9%) infections, respectively. Arboviral infections were diagnosed in 55 (7.9%) patients enrolled in the study. Bacterial zoonoses were identified among 118 (26.2%) patients; 16 (13.6%) had brucellosis, 40 (33.9%) had leptospirosis, 24 (20.3%) had Q fever, 36 (30.5%) had spotted fever group rickettsioses and 2 (1.8%) had typhus group rickettsioses (Fig 1). 6

Brucellosis

Aetiology

Brucellosis is caused by Brucella species, Gram-negative coccobacilli. Of a larger number of Brucella species with reservoirs in livestock and other animals, B abortus, B canis, B melitensis and B suis are recognized to cause human disease. The majority of human brucellosis worldwide is caused by B melitensis. 7

Reservoir, source and mode of transmission

Goats and sheep are the major reservoirs of B melitensis. Cattle are the major reservoir of B abortus, while B canis is mainly found in canines, and B suis in domestic and feral swine. In areas where cattle coexist with goats or are fed sheep offal, cattle can be infected with B melitensis. Brucella localises to the reproductive tract and mammary glands of animals and may be present in the blood, reproductive tract secretions, milk and meat. Humans acquire the infection through direct contact, airborne transmission during aerosolisation and foodborne transmission. Risk factors for human brucellosis in sub-Saharan Africa include assisting goat or sheep births and having contact with cattle. Consuming boiled or pasteurised dairy products has been found to be protective against brucellosis. 8

Incidence, complications and death

While it is well established that brucellosis is endemic in north Africa, the incidence of brucellosis is uncertain in many sub-Saharan African countries. 9 A study from northern Tanzania demonstrated that brucellosis incidence was stable at 35 cases per 100,000 person-years during 2007–2008 and 33 cases per 100,000 person-years during 2012–2014. 9 Prevalence estimates for chronic brucellosis are lacking. Data from retrospective studies indicate that the case fatality ratio for brucellosis is low, at approximately 1%. 2 During pregnancy, brucellosis can cause spontaneous abortion and fetal infection.
Manuela Carugati, Kajiru G Kilonzo and John A Crump

Clinical presentation
The clinical presentation of brucellosis is protean. Acute infection often presents as a nonspecific febrile illness. Chronic forms of brucellosis include focal involvement of the osteoarticular, reproductive and central nervous system as well as hepatitis, liver abscesses, endocarditis, lobar pneumonia and pleural effusions.7

Diagnosis
Diagnostic confirmation of acute brucellosis relies upon isolation of Brucella species from culture of clinical specimens or a four-fold rise in Brucella antibody titre between acute and convalescent sera obtained at least 14 days apart.11 While blood culture sensitivity is 50–90%, the sensitivity of bone marrow is 15–20% higher. The sensitivity and specificity for acute disease of Brucella paired serum agglutination tests exceed 90% in endemic areas.12 Neither the US Centers for Disease Control and Prevention nor the World Health Organization (WHO) has a specific case definition for chronic brucellosis. Finally, nucleic acid amplification tests are promising, but diagnostic performance varies substantially with the type of samples tested and the extraction methods used.13

Using blood cultures and serology as reference standards, the sensitivity of Brucella spp nucleic acid amplification tests (NAATs) has been reported as 61.0% in whole blood samples, 94.0% in serum samples and 97.1% in tissue samples from patients with a clinically active disease.14,15

Treatment
Tetracyclines and a parenteral aminoglycoside, or tetracyclines and rifampin are recommended by WHO for treatment of human brucellosis. The treatment duration is 6 weeks, except for spondylitis and osteomyelitis where 8–12 weeks of therapy is needed.

Prevention and control
Brucellosis prevention and control is based on interventions among both animals and humans. Animal interventions include vaccination of animal populations; testing animals for infection and slaughtering those infected; and pasteurisation of dairy products. Interventions among humans include use of personal protective equipment, such as an overall apron, rubber gloves, boots, eye protection and mask for meat workers and for those dealing with aborting animals or animals undergoing parturition; and hygiene measures, minimally including rinsing of hands in approved disinfectants and washing with soap and water after contact with animals. Superficial injuries should be treated with an approved antiseptic, such as 1% chloramine solution.

Intervention among humans are focused on specific groups such as abattoir workers and those dealing with aborting or parturient animals.

Leptospirosis
Aetiology
Leptospirosis is caused by spirochete bacteria in the genus Leptospira. There are 10 pathogenic species, and more than 250 pathogenic serovars. A large number of different Leptospira serogroups can cause human disease although predominant serogroups vary by year and by study.

Reservoir, source and mode of transmission
Pathogenic Leptospira have reservoirs in a wide range of animals including rodents and livestock and are shed in urine.16 The bacteria can survive for weeks to months in urine-contaminated water and soil. People are infected through direct or indirect contact with the urine of an infected animal. Rice farming, cleaning cattle waste, feeding cattle, farm work and increased exposure to cattle urine have been identified as risk factors for human leptospirosis in sub-Saharan Africa.17

Incidence, complications and death
A recent systematic review reported a prevalence of acute human leptospirosis in 2.3–19.8% of hospitalised patients with fever in Africa.18 Leptospirosis annual incidence in northern Tanzania has
and specificity. The case fatality ratio for leptospirosis is 5–15% among patients with severe illness. Among patients with pulmonary haemorrhage syndrome, the case fatality ratio can exceed 50%. Leptospirosis during pregnancy can cause fetal death.

Clinical presentation
Most infections are asymptomatic. Of symptomatic infections, 90% present as a nonspecific acute febrile illness 5–14 days after exposure, while 10% progress to severe illness with multi-organ dysfunction including renal failure, liver failure and pulmonary haemorrhagic syndrome.

Diagnosis
The diagnosis of leptospirosis is based on either a four-fold rise in Leptospira antibody titre between acute and convalescent sera obtained at least 14 days apart, or a single reciprocal titre of ≥1:800 measured by agglutination test. The isolation of Leptospira species from culture of clinical specimens is also a valid but insensitive diagnostic method. Due to the transience of leptospires in body fluids, whole blood should be cultured during the first week, and urine after the first week of illness. Finally, NAAT can be applied to a wide range of clinical samples; its sensitivity is higher when applied to whole blood samples within 2 weeks of symptom onset.

Reservoir, source and mode of transmission
Goats, sheep and cattle are the main reservoirs of C. burnetii. Infected animal birth products, urine, faeces and milk contain C. burnetii, and spore-like forms contaminate dust. As a consequence, people can be infected by direct contact with milk, urine, faeces, and afterbirth of infected animals; breathing dust contaminated by infected animals; and consuming unpasteurised dairy products of infected animals. Transmission through blood transfusion, from a pregnant woman to her fetus, and sexual transmission have been reported.

Incidence, complications and death
C. burnetii seroprevalence is 11–33% among small ruminants, ≤13% among cattle, and <8% among humans in African studies. In a human cohort study, Q fever accounted for 5% of febrile illness hospitalisations. Q fever is rarely fatal. An exception is Q fever related myocarditis that has a ≥25% case fatality ratio. The frequency of pregnancy complications in women developing Q fever is uncertain, although fetal death has been documented.

Clinical presentation
Of people infected with C. burnetii, 50% will develop symptoms. Acute infection is characterised by fever usually accompanied by rigors and myalgia 2–3 weeks after exposure. Acute infection can be complicated by hepatitis, pneumonia and meningoencephalitis. Less than 5% of people infected with C. burnetii develop a chronic infection that could persist for more than 6 months. The most common presentations of chronic Q fever are endocarditis, particularly in persons with underlying valvular disease, and vascular manifestations, including infection of vascular prostheses and aortic aneurysm. Less frequent presentations of chronic Q fever include osteomyelitis and hepatitis.

Diagnosis
In the presence of clinical symptoms, the diagnosis of acute and chronic Q fever may include the detection of C. burnetii by culture, polymerase chain reaction or immunohistochemistry. C. burnetii culture requires biosafety level three laboratories and involves the inoculation of specimens onto conventional cell cultures, embryonated hen yolk sacs or laboratory animals. C. burnetii NAAT can be applied to a wide range of clinical samples; its sensitivity is higher when applied to whole blood samples within 2 weeks of symptom onset. C. burnetii immunohistochemistry in tissue can be performed using several techniques including immunoperoxidase staining, a capture enzyme-linked immunosorbent assay, an enzyme-linked immunosorbent fluorescence assay system, or monoclonal antibodies. Finally, serologic testing based on indirect immunofluorescent assay (IFA) can support the diagnosis of acute and chronic Q fever. The demonstration of a four-fold rise in phase II immunoglobulin G (IgG) by IFA between acute and convalescent serum samples taken 4 weeks apart is used to confirm the diagnosis of acute Q fever. In contrast to acute infection, chronic Q fever is characterised by phase I IgG titres typically equal or greater than 1:1,024.

© Royal College of Physicians 2019. All rights reserved.
The diagnosis of rickettsiosis is based on the detection of *Rickettsia* spp by cell culture of blood and tissue specimens, immunohistochemical methods applied to tissue specimens, or blood and tissue specimen NAAT. While NAAT sensitivity in blood is low, NAAT of biopsy of eschar or rash material is sensitive. Furthermore, a four-fold rise in *Rickettsia* spp antibody titre between acute and convalescent sera obtained at least 14 days apart measured by an IFA is diagnostic. However, because of cross-reactivity of immune responses to rickettsial antigens, antibodies are group-specific but not species-specific.

**Treatment**

Doxycycline is the treatment of choice for rickettsioses. Treatment of patients with possible rickettsioses should be started when disease is suspected and should not await confirmatory testing, as certain infections can be rapidly progressive. Treatment duration is 7 days.

**Prevention and control**

Rickettsioses prevention is based on both vector and human interventions. Vector interventions consist in the use of insecticides. Human interventions are based on limiting the exposure to the vectors. This goal could be achieved wearing protective clothing and using insect repellent, such as diethyl-m-toluamide and permethrin, when undertaking activities where human contact with ticks, mites or fleas may occur such as during bushwalking and camping in infected areas.
Bacterial zoonoses in Africa

Although not widely appreciated or studied, bacterial zoonoses are likely to be endemic in many African countries and cause substantial human morbidity and mortality. In addition to causing human infections, bacterial zoonoses have important effects on the livelihoods of rural communities through their impacts on livestock fertility, growth, productivity and survival. Here, close contact with animals and their environments heightens risk for infection, human and livestock healthcare services are limited, and livestock represent a major source of nutrition and income for families. Despite their substantial impact on both human and animal health, bacterial zoonoses have been neglected because the burden of disease is poorly quantified is borne largely by disadvantaged populations with little political voice in low-resource areas. One Health is the collaborative effort of multiple disciplines to attain optimal and equitable health for people, animals and the environment. Bacterial zoonoses lend themselves to One Health approaches to management, prevention and control.

For clinicians working in low-resource settings, bacterial zoonoses present a number of challenges. From a diagnostic perspective difficulties include limited healthcare provider awareness; non-specific clinical presentation and frequent misdiagnosis with malaria; prior antimicrobial administration that may hamper the ability to detect bacteria; presentation later in the course of the illness when the bacteraemic phase has passed; lack of accurate tests at point-of-care and unavailability of confirmatory tests, and the limited diagnostic accuracy of single sample serology. Regarding patient management challenges, WHO Integrated Management of Adolescent and Adult Illness (IMAI) District Clinician Manual algorithms for severe febrile illness recommend ceftriaxone or ampicillin plus gentamicin. However, while these regimens would be effective for leptospirosis, they are not suitable for the treatment of brucellosis, Q fever and rickettsiosis. 

Livestock and environmental interventions have the potential to effectively reduce the magnitude of bacterial zoonotic infections from the animal and environmental reservoirs, generating benefits to all who are epidemiologically linked with the source of the infection. The prevention and control of brucellosis, leptospirosis, Q fever and rickettsiosis is centred on approaches targeting animal reservoirs, environmental sources, vectors and humans. When implemented, such approaches contribute to better outcomes for human and animal health than those based exclusively on treatment of human infections. Both clinicians’ awareness and resources for the development and implementation of control measures will be crucial for addressing bacterial zoonoses in Africa.

Acknowledgements

We acknowledge Prof Matthew P Rubach, Robert Chuwa, Dr Kate M Thomas and the staff of Duke Collaboration at Kilimanjaro Christian Medical Centre (Moshi, United Republic of Tanzania).

Table 1. Tests for the diagnosis of brucellosis, leptospirosis, Q fever and rickettsiosis

|                  | Culture | Nucleic acid amplification | Serology | Comments                                                                 |
|------------------|---------|----------------------------|----------|---------------------------------------------------------------------------|
| Brucellosis      | X       | X                          | X        | Culture: bone marrow cultures are more sensitive than blood cultures.     |
|                  |         |                            |          | NAAT: sensitivity is highest in tissue samples.                           |
|                  |         |                            |          | Serology: four-fold rise in Brucella antibody titre between paired sera. |
| Leptospirosis    | X       | X                          | X        | Culture: poor sensitivity.                                               |
|                  |         |                            |          | Serology: four-fold rise in Leptospira antibody titre between paired sera  |
|                  |         |                            |          | or single titre ≥1:800                                                    |
| Q fever          | X       | X                          | X        | NAAT: sensitivity is highest for whole blood samples within 2 weeks of symptom onset. |
|                  |         |                            |          | Serology: acute Q fever, four-fold rise in phase II IgG between paired sera; chronic Q fever, phase I IgG titres ≥1:1,024. |
| Rickettsiosis    | X       | X                          | X        | NAAT: sensitivity in blood is low, but high when applied to skin biopsy.  |
|                  |         |                            |          | Serology: four-fold rise in Rickettsia spp antibody titre between paired sera. |

IgG = immunoglobulin G; NAAT = nucleic acid amplification test.

Table 2. Treatment recommendations for brucellosis, leptospirosis, Q fever and rickettsiosis

| Treatment | Duration |
|-----------|----------|
| Brucellosis | Tetracyclines plus parenteral aminoglycoside or tetracyclines plus rifampin. 6 weeks. If spondylitis and osteomyelitis, 8–12 weeks. |
| Leptospirosis | Mild disease: doxycycline or amoxicillin. 7 days. Severe disease: penicillin G or ceftriaxone. |
| Q fever | Acute Q fever: doxycycline. Acute Q fever: 14 days. Chronic Q fever: doxycycline and hydroxychloroquine. Chronic Q fever: 18–24 months. |
| Rickettsiosis | Doxycycline. 7 days. |
References

1. Feikin DR, Olack B, Bigogo GM et al. The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya. PLoS One 2011;6:e16085.

2. Murray CJ, Ortblad KF, Guinovart C et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 2014;384:1005–70.

3. Reyburn H, Mbatia R, Drakeley C et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2006;332:1212–5.

4. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:417–32.

5. Maze MJ, Bassat Q, Feasey NA et al. The epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and management. Clin Microbiol Infect 2018;24:808–14.

6. Crump JA, Ramadhan HS, Morissette AB et al. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis 2011;52:341–8.

7. Corbel MJ. Brucellosis in humans and animals. Geneva: World Health Organization; 2006. www.who.int/cs/sresources/publications/Brucellosis.pdf.

8. Cash-Goldwater S, Maze MJ, Rubach MP et al. Risk factors for human brucellosis in northern Tanzania. Am J Trop Med Hyg 2018;98:598–606.

9. Dean AS, Crump L, Greter H et al. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis 2012;6:e1865.

10. Carugati M, Biggs HM, Maze MJ et al. Incidence of human brucellosis in the Kilimanjaro region of Tanzania in the periods 2007–2008 and 2012–2014. Trans R Soc Trop Med Hyg 2018;112:136–43.

11. Centers for Disease Control and Prevention. Brucellosis 2010 case definition. Atlanta: CDC. www.cdc.gov/ndss/conditions/brucellosis/case-definition/2010/.

12. Rubach MP, Halliday JEB, Cleveland S. Brucellosis in low-income and middle-income countries. Curr Opin Infect Dis 2013;26:604–12.

13. Arag GF. Updates on laboratory diagnosis of brucellosis. Int J Antimicrob Agents 2010;36:S512–7.

14. Morata P, Queipo-Ortuno MI, Reguera JM et al. Diagnostic yield of a PCR assay in focal complications of brucellosis. J Clin Microbiol 2001;39:3743–6.

15. Zerva L, Bourantas K, Mitka S et al. Serum is the preferred clinical specimen for diagnosis of human brucellosis by PCR. J Clin Microbiol 2001;39:1661–4.

16. Allan KJ, Halliday JEB, Moseley M et al. Assessment of animal hosts of pathogenic Leptospira in northern Tanzania. PLoS Negl Trop Dis 2018;12:e0006444.

17. Maze MJ, Cash-Goldwater S, Rubach MP et al. Risk factors for human acute leptospirosis in northern Tanzania. PLoS Negl Trop Dis 2018;12:e0006372.

18. Allan KJ, Biggs HM, Halliday JEB et al. Epidemiology of leptospirosis in Africa: a systematic review of a neglected zoonosis and a paradigm for ‘One Health’ in Africa. PLoS Negl Trop Dis 2015;9:e0003899.

19. Maze MJ, Biggs HM, Rubach MP et al. Comparison of the estimated incidence of acute leptospirosis in the Kilimanjaro region of Tanzania between 2007–08 and 2012–14. PLoS Negl Trop Dis 2016;10:e0005165.

20. Centers for Disease Control and Prevention. Leptospirosis 2013 case definition. Atlanta: CDC. www.cdc.gov/ndss/conditions/leptospirosis/case-definition/2013/.

21. Musso D, Bernard LS, Musso D et al. Laboratory diagnosis of leptospirosis: a challenge. J Microbiol Infect Dis 2013;6:245–52.

22. Vanderburg S, Rubach MP, Halliday JEB et al. Epidemiology of Coxiella burnetii infection in Africa: a OneHealth systematic review. PLoS Negl Trop Dis 2014;8:e2787.

23. Wardrop NA, Thomas LF, Cook EA et al. The sero-epidemiology of Coxiella burnetii in humans and cattle, Western Kenya: evidence from a cross-sectional study. PLoS Negl Trop Dis 2016;10:e0005032.

24. Prabhute M, Nicholson W, Roche AJ et al. Q fever, spotted fever group and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania. Clin Infect Dis 2011;53:e8–15.

25. Anderson A, Bormer H, Fournier PE et al. Diagnosis and management of Q fever, United States, 2013. MMWR 2013;62:1–23.

26. Clark NJ, Soares Maghazaie R. Airborne geographical dispersal of Q fever from livestock holdings to human communities: a systematic review and critical appraisal of evidence. BMC Infect Dis 2018;18:218.

27. Parola P, Raoult D. Tropical rickettsioses. Clin Dermatol 2006;24:191–200.

28. Taylor AJ, Paris OH, Newton PN. A systematic review of mortality from untreated scrub typhus. PLoS Negl Trop Dis 2015;9:e0003971.

29. Adjemian J, Parks S, McElroy K et al. Murine typhus in Austin, Texas, USA, 2008. Emerg Infect Dis 2010;16:412–7.

30. Parola P, Paddock CD, Socoloschi C et al. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 2013;26:657–702.

31. Centers for Disease Control and Prevention. Rocky Mountain Spotted Fever 2008 case definition. Atlanta: CDC. www.cdc.gov/ndss/conditions/rocky-mountain-spotted-fever/case-definition/2008/.

32. Grace D. Mapping of poverty and likely zoonoses hotspots. Zoonoses project 4. Report to the UK department for international development. Nairobi: International Livestock Research Institute. http://hdl.handle.net/10568/21161.

33. Cleaveland S, Sharp J, Abela-Ridder B et al. One Health contributions towards more effective and equitable approaches to health in low- and middle-income countries. Phil Trans R Soc B 2017;372:20160168.

34. Centers for Disease Control and Prevention. One Health basics. Atlanta: CDC. www.cdc.gov/onehealth/basics/index.html.

35. Zong H, Nsanzawa KW, Mitchell ST et al. Mixed methods survey of zoonotic disease awareness and practice among animal and human healthcare providers in Moshi, Tanzania. PLoS Neglect Trop Dis 2016;10:e0004467.

36. Crump JA, Morissette AB, Nicholson W et al. Etiology of severe non-malaria febrile illness in northern Tanzania: a prospective cohort study. PLoS Negl Trop Dis 2013;7:e22324.

37. Levett PN, Haake DA. Leptospira species. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 7th ed. Churchill Livingstone, 2009.

38. Pettig CA, Polage CR, Quinn TC et al. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 2006;42:377–82.

39. De Glanville WA, Conde-Alvarex R, Moriyon I et al. Poor performance of the rapid test for human brucellosis in health facilities in Kenya. PLoS Negl Trop Dis 2017;11:e0005508.

40. World Health Organization. IMAI District Clinician Manual: Hospital care for adults and children. Geneva: WHO, 2011. www.who.int/hiv/pub/ima/ima2011/en/.

Address for correspondence: Prof John A Crump, Centre for International Health, Dunedin School of Medicine, University of Otago, PO Box 56, Dunedin 9054, New Zealand.

Email: john.crump@otago.ac.nz

© Royal College of Physicians 2019. All rights reserved.